RSHN
heliosDX and RushNet Inc. Sign Binding Letter of Intent to Acquire Laboratory and Target Additional Laboratory Acquisitions
9:04 am ET June 7, 2021 (Newsfile) Print
Alpharetta, Georgia--(Newsfile Corp. - June 7, 2021) - RushNet, Inc (OTC PINK: RSHN) ("RushNet"
with merger/acquisition target heliosDX, is pleased to announce a Binding Letter of Intent by heliosdDX to acquire a privately held laboratory with $10,000,000 annual revenues processing more than 5,000 tests monthly with a capacity of 12,000 monthly UDS tests.
The acquisition further increases the National footprint of heliosDX while also reducing costs, tripling the sales force, and increasing the capacity to process substantially more testing in the UDS portfolio. Significantly, the types of tests offered by heliosDX coupled with those offered by the new facility create a more expansive combined testing capacity. It is apparent as the market continues to evolve, we should attain an even higher sales volume and footprint to secure larger national contracts, particularly with insurance carriers and medical groups, which is critical to the long-term success of heliosDX. The acquisition would expedite this process along with offering more testing options at the target labs clinic sites which are not presently available, including PCR, Allergy and PGx. Conversely, the target laboratory will expand heliosDX testing capabilities and portfolio with Oral Fluid Toxicology.
Upon closing of the acquisition, we should have combined annual revenues exceeding $16,000,000. The operational efficiencies should decrease costs and increase operating margins by 10%. Accordingly, the opportunity for growth and enhanced bottom-line is substantial. The expected revenue after a full 12 months of combined operations is estimated to be $20,000,000 to $25,000,000. Additionally, with the enhanced production capacity, heliosdDX will be able to process more than 18,000 UDS samples monthly. Upon close, heliosdDX will be processing more than 7,500 UDS samples monthly with an expected growth target of 10,000 UDS monthly. This transaction not only enhances the bottom-line, but rings in a new era of scalability for heliosDX. The expected closing timeframe for this acquisition is slated for Mid-September to Early October 2021. However, both parties are interested in expediting the closing if possible.
In addition to this acquisition, heliosDX has identified a second laboratory to acquire. This laboratory likewise offers the ability for heliosDX to further enhance its operating margin as well as sales. An expected execution of the Binding Letter of Intent with targeted laboratory is for late June to early July 2021. This lab acquisition would bring an additional 1,000,000 dollars in annual revenue. More importantly, this is a strategic acquisition for location and contracting potential.
Lastly, heliosDX continues to search the market for additional laboratories for acquisition. A third laboratory has been identified and preliminary numbers shared, but negotiations have yet to begin. An update will be provided as more information is readily available.
At this time, due to the nature of such agreement and potential of disruption, each privately held company has asked for anonymity. A combined press release will be issued by the entities when appropriate.
heliosDX and RushNet Inc. Sign Binding Letter of Intent to Acquire Laboratory and Target Additional Laboratory Acquisitions
9:04 am ET June 7, 2021 (Newsfile) Print
Alpharetta, Georgia--(Newsfile Corp. - June 7, 2021) - RushNet, Inc (OTC PINK: RSHN) ("RushNet"
with merger/acquisition target heliosDX, is pleased to announce a Binding Letter of Intent by heliosdDX to acquire a privately held laboratory with $10,000,000 annual revenues processing more than 5,000 tests monthly with a capacity of 12,000 monthly UDS tests. The acquisition further increases the National footprint of heliosDX while also reducing costs, tripling the sales force, and increasing the capacity to process substantially more testing in the UDS portfolio. Significantly, the types of tests offered by heliosDX coupled with those offered by the new facility create a more expansive combined testing capacity. It is apparent as the market continues to evolve, we should attain an even higher sales volume and footprint to secure larger national contracts, particularly with insurance carriers and medical groups, which is critical to the long-term success of heliosDX. The acquisition would expedite this process along with offering more testing options at the target labs clinic sites which are not presently available, including PCR, Allergy and PGx. Conversely, the target laboratory will expand heliosDX testing capabilities and portfolio with Oral Fluid Toxicology.
Upon closing of the acquisition, we should have combined annual revenues exceeding $16,000,000. The operational efficiencies should decrease costs and increase operating margins by 10%. Accordingly, the opportunity for growth and enhanced bottom-line is substantial. The expected revenue after a full 12 months of combined operations is estimated to be $20,000,000 to $25,000,000. Additionally, with the enhanced production capacity, heliosdDX will be able to process more than 18,000 UDS samples monthly. Upon close, heliosdDX will be processing more than 7,500 UDS samples monthly with an expected growth target of 10,000 UDS monthly. This transaction not only enhances the bottom-line, but rings in a new era of scalability for heliosDX. The expected closing timeframe for this acquisition is slated for Mid-September to Early October 2021. However, both parties are interested in expediting the closing if possible.
In addition to this acquisition, heliosDX has identified a second laboratory to acquire. This laboratory likewise offers the ability for heliosDX to further enhance its operating margin as well as sales. An expected execution of the Binding Letter of Intent with targeted laboratory is for late June to early July 2021. This lab acquisition would bring an additional 1,000,000 dollars in annual revenue. More importantly, this is a strategic acquisition for location and contracting potential.
Lastly, heliosDX continues to search the market for additional laboratories for acquisition. A third laboratory has been identified and preliminary numbers shared, but negotiations have yet to begin. An update will be provided as more information is readily available.
At this time, due to the nature of such agreement and potential of disruption, each privately held company has asked for anonymity. A combined press release will be issued by the entities when appropriate.
